1,527 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Values First Advisors Inc.

Values First Advisors Inc. bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 1,527 shares of the company’s stock, valued at approximately $174,000.

Several other institutional investors have also recently added to or reduced their stakes in PCVX. Signaturefd LLC raised its holdings in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after purchasing an additional 358 shares during the period. Allspring Global Investments Holdings LLC increased its position in Vaxcyte by 1.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 347,474 shares of the company’s stock valued at $39,706,000 after buying an additional 3,922 shares in the last quarter. Raymond James & Associates raised its stake in Vaxcyte by 17.0% during the 3rd quarter. Raymond James & Associates now owns 81,235 shares of the company’s stock worth $9,283,000 after buying an additional 11,798 shares during the period. Blue Trust Inc. boosted its holdings in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Finally, Riverview Trust Co bought a new stake in shares of Vaxcyte during the third quarter valued at approximately $27,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $112.94 on Friday. The company has a market capitalization of $12.29 billion, a price-to-earnings ratio of -26.39 and a beta of 0.99. Vaxcyte, Inc. has a 52-week low of $45.61 and a 52-week high of $121.06. The company has a 50-day simple moving average of $106.09 and a two-hundred day simple moving average of $84.17.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same period in the prior year, the business earned ($0.70) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PCVX shares. BTIG Research lifted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Leerink Partners lifted their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Jefferies Financial Group upped their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America lifted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Needham & Company LLC increased their price objective on Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Buying and Selling at Vaxcyte

In related news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares in the company, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at $37,822,574.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 92,098 shares of company stock worth $9,937,773 in the last quarter. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.